On January 24, 2022 Patrys reported the completion of the first engineering run for its lead asset PAT-DX1 (Press release, Patrys, JAN 24, 2022, View Source [SID1234606695]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The purification of PAT-DX1 from the cell harvest resulted in lower drug product recoveries than expected. Our team is now working with the Contract Development Manufacturing Organisation (CDMO) to implement improvements to the large-scale purification process.

This will mean an extension of the anticipated timeline to start our first in human study for PAT-DX1.